Do we really need an Artificial Heart? No!! John V. Conte, MD, Professor of Surgery Johns Hopkins University School of Medicine

Similar documents
Further devices to treat heart failure

Pediatric Mechanical Circulatory Support - What to Use

Status of Implantable VADs

Mechanical Circulatory Support in the Management of Heart Failure

Implantable Ventricular Assist Devices and Total Artificial Hearts. Policy Specific Section: June 13, 1997 March 29, 2013

Update on Mechanical Circulatory Support. AATS May 5, 2010 Toronto, ON Canada

Ventricular Assist Devices for Permanent Therapy: Current Status and Future

New ventricular assist devices. FW Mohr Clinical seminar: Devices for severe heart failure ESC congress Stockholm 2010

Giving your heart strength. Ventricular Assist Device.

Fifth INTERMACS annual report: Risk factor analysis from more than 6,000 mechanical circulatory support patients

VAD come Destination therapy nell adulto con Scompenso Cardiaco

LVAD Complications, Recovery

Pediatric Mechanical Circulatory Support (MCS)

Concomitant Aortic Valve Procedures in Patients Undergoing Implantation of Continuous-Flow LVADs: An INTERMACS Database Analysis

VAD Program Alert: Practice Change regarding CPR

Left Ventricular Assist Devices (LVADs): Overview and Future Directions

Management of Cardiogenic Shock. Dr Stephen Pettit, Consultant Cardiologist


เอกราช อร ยะช ยพาณ ชย

Risk Factors for Adverse Outcome after HeartMate II Jennifer Cowger, MD, MS St. Vincent Heart Center of Indiana

None. Declaration of conflict of interest

Right Ventricular Failure: Prediction, Prevention and Treatment

Destination Therapy SO MUCH DATA IN SUCH A SMALL DEVICE. HeartWare HVAD System The ONLY intrapericardial VAD approved for DT.

LVADs as a long term or destination therapy for the advanced heart failure

Mechanical Support in the Failing Fontan-Kreutzer

Extra Corporeal Life Support for Acute Heart failure

ECMO as a bridge to durable LVAD therapy. Jonathan Haft, MD Department of Cardiac Surgery University of Michigan

End Stage Heart Failure - Time to Bring the Hammer Down

Advances in Advanced Heart Failure Therapies. Disclosures. Management Algorithm for Patients in Cardiogenic Shock

Mechanical assist patient selection, device selection, and outcomes

Modern Left Ventricular Assist Devices (LVAD) : An Intro, Complications, and Emergencies

Surgical Options for Advanced Heart Failure

MEDICAL POLICY Ventricular Assist Devices

VENTRICULAR ASSIST DEVICES AND TOTAL ARTIFICIAL HEARTS

Readmissions: an unavoidable nemesis

How to Develop a Comprehensive Ventricular Assist Device Program

HeartWare ADVANCE Bridge to Transplant Trial and Continued Access Protocol Update

A Validated Practical Risk Score to Predict the Need for RVAD after Continuous-flow LVAD

I have nothing to disclose.

Index. Note: Page numbers of article titles are in boldface type.

Multicenter Study of MagLev Technology in Patients Undergoing Mechanical Circulatory Support Therapy with HeartMate 3 (MOMENTUM 3) Long Term Outcomes

ORIGINAL ARTICLE. Alexander M. Bernhardt a, *, Theo M.M.H. De By b, Hermann Reichenspurner a and Tobias Deuse a. Abstract INTRODUCTION

Management of Acute Shock and Right Ventricular Failure

How do Readmissions Impact Survival among Patients with Continuous-Flow Left Ventricular Assist Devices? Findings from INTERMACS

VENTRICULAR ASSIST DEVICES AND TOTAL ARTIFICIAL HEARTS

Ventricular Assist Devices and Total Artificial Hearts

Implantable Ventricular Assist Devices and Total Artificial Hearts

Why Children Are Not Small Adults? Treatment of Pediatric Patients Needing Mechanical Circulatory Support

Andrew Civitello MD, FACC

Name of Policy: Ventricular Assist Devices and Total Artificial Hearts

MEDICAL POLICY SUBJECT: VENTRICULAR ASSIST DEVICES

Lessons learned from ENDURANCE, ROADMAP, MedaMACS, and how to go forward?

Implantable Ventricular Assist Devices and Total Artificial Hearts

Seventh INTERMACS annual report: 15,000 patients and counting

Recent Trials With Durable LVADs: Is There a Superior Device?

ECMO as a Bridge to Heart Transplant in the Era of LVAD s.

Minimally Invasive Insertion of HVAD

Medical Policy. MP Total Artificial Hearts and Implantable Ventricular Assist Devices

Implantable Ventricular Assist Devices and Total Artificial Hearts

EMS: Care of the VAD Patient. Brittany Butzler BSN RN VAD Coordinator Froedtert and the Medical College of WI

Advanced Heart Failure and Transplant Cardiology

Echo assessment of patients with an ECMO device

Facts. STRONG Risk Factors for HF* LVAD, BiVAD, RVAD, HVAD 10/21/ million adults in the US have heart failure.

Size Limitation for Current Continuous Flow Pumps: How young can we go?

QUICK REFERENCE HEARTWARE HVAD PUMP FLOW INDEX

Disclosures. No disclosures to report

Surgical Thrombectomy for PE: Is it Making a Comeback

CHANGING THE WAY HEART FAILURE IS TREATED. VAD Therapy

07/17/2014. Thursday, July 17, 14

LEFT VENTRICULAR ASSIST DEVICE COMPLICATIONS. Daniel Vargas, MD Section of Cardiothoracic Imaging University of Colorado Anschutz Medical Campus

Counterpulsation. John N. Nanas, MD, PhD. Professor and Head, 3 rd Cardiology Dept, University of Athens, Athens, Greece

Innovative ECMO Configurations in Adults

Sixth INTERMACS annual report: A 10,000-patient database

Regional Differences in Utilization and Outcomes of Left Ventricular Assist Devices: Insights from the INTERMACS Registry

Ventricular Assist Device: Are Early Interventions Superior? Hamang Patel, MD Section of Cardiomyopathy & Heart Transplantation

Description. Section: Surgery Effective Date: April 15, Subsection: Transplant Original Policy Date: September 13, 2012 Subject:

Minimally invasive left ventricular assist device placement

Evaluation of Native Left Ventricular Function During Mechanical Circulatory Support.: Theoretical Basis and Clinical Limitations

PROVEN. TRUSTED. COMMITTED. HeartWare HVAD System

Complications of VAD therapy - RV failure

Mechanical Cardiac Support in Acute Heart Failure. Michael Felker, MD, MHS Associate Professor of Medicine Director of Heart Failure Research

Total Artificial Hearts and Implantable Ventricular Assist Devices

Heart Transplant vs Left Ventricular Assist Device in Heart Transplant-Eligible Patients

HEARTMATE II LEFT VENTRICULAR ASSIST SYSTEM. HeartMate II Left Ventricular Assist Device

Artificial Heart Program

WHAT S NEW IN HEART FAILURE

Total Artificial Hearts and Implantable Ventricular Assist Devices

Right Heart Failure in LVAD patients: Prevention and Management.

Ramani GV et al. Mayo Clin Proc 2010;85:180-95

Understanding the Pediatric Ventricular Assist Device

Strengthening Your VAD Program

Description. Section: Surgery Effective Date: January 15, 2015 Subsection: Transplant Original Policy Date: September 13, 2012 Subject:

Case - Advanced HF and Shock (INTERMACS 1)

Ventricular Assist Devices and Emergency Services

AUTOLOGS TM ATLAS ON DEMAND DATA WITH EVERY PATIENT VISIT

Jennifer A. Brown The Cleveland Clinic School of Perfusion Cleveland, Ohio

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Mechanical Cardiac Support and Cardiac Transplant: The Role for Echocardiography

THE USE of VENTRICULAR ASSIST DEVICES in CHILDREN: CURRENT OPTIONS & FUTURE TRENDS

Translating Device and Mechanical Support Guidelines to ACHD Research. Timothy M. Maul, CCP, PhD Perfusionist Sr. Research Scientist

Transcription:

Do we really need an Artificial Heart? No!! John V. Conte, MD, Professor of Surgery Johns Hopkins University School of Medicine Division of Cardiac Surgery The Johns Hopkins Medical Institutions

Conflict of Interest Statement No Financial Interests Investigator Thoratec: Heartmate 2 LVAD Heartware: HVAD LVAD Abiomed : Abiocor TAH

Really Francisco? Really?

The concept of the Artificial Heart is exciting!. Artificial Heart is sexy!

Artificial Heart Images : 1960 s, President Kennedy, Hope, Optimism Space flight We will put a man on the moon by the end of the decade Artificial Heart Artificial Heart Program created by the National Heart Institute (NHI) with a national mission to reduce death and disability from heart disease through the development and use of a variety of safe,effective and reliable cardiac assist and total replacement systems.

Artificial Hearts

Artificial Heart Images

Artificial Heart Images

Artificial Heart

Mechanical Circulatory Support Heart pump Ventricular Assist Device

Ventricular Assist Devices Implantable Pump Percutaneous Lead Controller Batteries

Mechanical Circulatory Support Images No Rock Stars here! Sexy?

Image Problem? We don t need an Artificial Heart!

Why don t we need artificial Heart? Results not better TAH more complicated to implant to care for Indications sketchy at best Less convenient for patient More expensive Good alternatives, applicable for all patients

J Copeland. J Thorac Cardiovasc Surg2012;143:727-34

TAH Survival 16 yrs 93-2009 101 pts Mean support 87 days J Copeland. Thorac Cardiovasc Surg2012;143:727-34

Strokes in 7.9% of cases Take-back for hemorrhage in 24.7% of cases 68% survived to transplant J Copeland. Thorac Cardiovasc Surg2012;143:727-34

Competing Outcomes Analysis (n=281) Pagani F, Miller L, Russell S, JAAC: Vol 54, No 4, 2009. 18

383 patients between 2000 and 2010 French multicentricgroupe de Réflexion sur l Assistance Mécanique (GRAM) registry. 66% paracorporealbivad, 24% TAH, 10% implantable BiVADor 63% successful bridgeor wean Kirsch M. J Heart Lung Transplant 2012

Survival while on support and after heart transplantation did not differ significantly in patients supported with paracorporealbivads, implantable BiVADs, or the TAH. Kirsch M. J Heart Lung Transplant 2012

Outcomes 9% of BiVADsweaned off support! You can t be weaned off support if your heart is in a bucket!

June 2006 June 2009

Only 3.6% of devices inserted were TAH! All investigational devices excluded in INTERMACS so. % actually much lower than 3.6%

Cleveland J. J Heart Lung Transplant 2011;30:862-9

Pulsatile vs Continuous Flow Cleveland J. J Heart Lung Transplant 2011;30:862-9

June 2006-June 2011

99 TAH /4366 Implants 2.13 % of Implants! 1.17 % of Implants

Ease of Implant -TAH Won t fit all patients- too large Abiofit Algorithm Big operation 4 suture lines Full sternotomy Cardiopulmonary bypass

Ease of implant -LVAD Small enough for nearly all adults Some advertise No pump pocket 2 rather than 4 potential bleeding sites One suture line and apical cannulation Can be put in without cpb Minimally invasive approach

Non Sternotomy LVAD Insertion

Patient ease of use

Patient ease of use s

Patient ease of use Implanted Battery Thoracic Unit Implanted TET Coil Implanted Controller

Magnetically Coupled Resonators Magnetic Resonance to wirelessly transfer energy Based on work of Nikola Tesla early 20 th century Presented at STS 2012

J Copeland. J Thorac Cardiovasc Surg2012;143:727-34

Discussion There really are no data presented to convince the reader that in fact these patients weren t eligible for an LVAD In general, our experience has -DrHariMallidi, shown that patients Stanford with elevated PAP for the most part need LVAD therapy alone. Right Their RV atrial can pressure be managed was 20 with mm inotropes Hg, pulmonary or a temporary artery assist systolic device with pressure (later) was removal 55 mmhg, of the and device wedge or pressure weaning was from the 30 inotropes. mm Hg. DrHannah -DrHariMallidi, Copeland Stanford

If we don t need an artificial heart.. What do we need?

New TAH = Creative VAD Adaptation

Thank you!